Single dose injection snoreplasty: investigation or treatment?

Al-Jassim, A H; Lesser, T. H. J.

doi:10.1017/s0022215108002648

Cited by 8 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2008, Al-Jassim and Lesser [13], used injection snoreplasty in 60 primary snorers, as a part of their assessment, in order to rule out if the snoring was originated at the palate or anywhere else, so they could eventually decide if further and more aggressive palatal surgery could be indicated. They did not evaluate OSAS patients.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Submucosal Sodium Tetradecyl Sulfate in the Soft Palate as a Treatment of the Mild Obstructive Sleep Apnea Syndrome: A Pilot Study

et al. 2012

View full text Add to dashboard Cite

Background. As described by Mair et al. in 2001, snoreplasty, the application of sclerosant agents in the palate is a promising and cheap alternative to treat snoring. We decided to try this kind of therapy for the management of mild sleep apnea. Study Design. Experimental, longitudinal, prospective, nonrandomized, self-controlled pilot study. Methods. 11 patients were included, all of them with a polysomnographic study showing an Apnea-Hypopnea Index (AHI) from 5 to 20, and with a Müller maneuver showing only retropalatal collapse. Results. We found significant decrease in the number of apneas hypopneas and oxygen desaturation as well as in the snoring index (P < 0.05), although no differences were found in the number of arousals. Conclusion. Sclerosant agents might become a relevant part in the treatment of sleep apnea, in very well-selected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Submucosal Sodium Tetradecyl Sulfate in the Soft Palate as a Treatment of the Mild Obstructive Sleep Apnea Syndrome: A Pilot Study

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The two most common agents used are sodium tetradecyl sulfate (STS) and a combination of 2% lidocaine and ethanol with no reported difference in effectiveness. Prospective cohort studies have highlighted the impact of injection snoreplasty in reducing both total snoring time and snoring intensity at 6–12 months with minimal side effects, 76 , 77 , 78 however its efficacy reduces over time. 79 Level of evidence : C. Recommendation with level of certainty : Low .…”

Section: Recommendations For Treatmentmentioning

confidence: 99%

Australasian Sleep Association position statement on consensus and evidence based treatment for primary snoring

Sarkis

Jones

et al. 2023

Respirology

View full text Add to dashboard Cite

Primary snoring impacts a significant portion of the adult population and has the potential to significantly impair quality of life. The purpose of these guidelines is to provide evidence‐based recommendations to assist Australasian practitioners in the management of adult patients who present with primary snoring without significant obstructive sleep apnoea. The Timetable, Methodology and Standards by which this Position Statement has been established is outlined in the Appendix S1. The main recommendations are: Weight loss, and reduced alcohol consumption should be recommended, where appropriate If clinical judgement dictates, benzodiazepine and opioid reduction or avoidance may be advised Positional therapy should be considered in supine dominant snorers In dentate patients, Mandibular advancement devices (MAD) should be recommended as a first line treatment following assessment by both an appropriate Dentist and Sleep physician Continuous positive airway pressure (CPAP) devices may be recommended in patients with primary snoring in those already committed to their use or willing to try Surgical treatment of primary snoring by an appropriately credentialled surgeon may be advised and includes nasal (adjunctive), palatal and other interventions This position statement has been designed based on the best available current evidence and our combined expert clinical experience to facilitate the management of patients who present with primary snoring. It provides clinicians with a series of both non‐surgical and surgical options with the aim of achieving optimal symptom control and patient outcomes. This is the first such set of recommendations to be established within Australasia and has also been reviewed and endorsed by the Australasian Sleep Association.

show abstract

“…La búsqueda de un tratamiento que proporcione una mejoría de la patología, garantizando la adherencia y perdurabilidad del mismo, hace que indaguemos en diferentes opciones terapéuticas (14)(15)(16)(17). Una alternativa son los procedimientos realizados en el consultorio que ofrecen una solución rápida, menos invasiva con resultados a corto y largo plazo, siempre y cuando la selección del paciente sea la adecuada (15,16,(18)(19)(20)(21).…”

Section: Uso De Tetradecil Sulfato De Sodio Aplicado Submucoso En Palunclassified

Uso de tetradecil sulfato de sodio aplicado submucoso en paladar blando como tratamiento del SAOS leve

Reyes¹,

Labra²,

Delgado³

et al. 2017

Acta otorrinolaringol cir cabeza cuello

View full text Add to dashboard Cite

Introducción: El Síndrome de Apnea Obstructiva del Sueño (SAOS) es uno de los trastornos de sueño más frecuentes, asociada con el riesgo cardiovascular. En la actualidad se ha descrito el uso de esclerosantes en el manejo del ronquido simple, no en la apnea del sueño leve. Objetivo: Evaluar la eficacia de este procedimiento para los pacientes con SAOS de intensidad leve con sitio exclusivo de obstrucción en paladar blando. Diseño: Estudio cuasi-experimental no controlado de antes y después. Métodos: Se incluyeron 11 pacientes con SAOS leve, con sitio de obstrucción exclusivo en paladar blando. Se realizó polisomnografía basal y de control a los 6 meses del tratamiento. Se usó tetradecil sulfato de sodio 3%, submucoso en paladar blando 1ml. en la línea media y 0.5 ml paramedial. Se evaluó el índice de ronquido, de apnea/hipopnea (IAH), saturación de oxígeno y despertares. Discusión: Aunqueel número de pacientes es muy pequeño, este es el único antecedente del uso de esclerosantes en el tratamiento de apnea del sueño leve, siendo un procedimiento rápido, económico y poco molesto. Se observó mejoría en los parámetros evaluados exceptuando los despertares. Conclusiones: La inyección de esclerosantes podría ser un tratamiento de elección en pacientes con SAOS leve que cumplan con los criterios de obstrucción ya nombrados.

show abstract

Single dose injection snoreplasty: investigation or treatment?

Cited by 8 publications

References 16 publications

Efficacy of Submucosal Sodium Tetradecyl Sulfate in the Soft Palate as a Treatment of the Mild Obstructive Sleep Apnea Syndrome: A Pilot Study

Efficacy of Submucosal Sodium Tetradecyl Sulfate in the Soft Palate as a Treatment of the Mild Obstructive Sleep Apnea Syndrome: A Pilot Study

Australasian Sleep Association position statement on consensus and evidence based treatment for primary snoring

Uso de tetradecil sulfato de sodio aplicado submucoso en paladar blando como tratamiento del SAOS leve

Contact Info

Product

Resources

About